Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies

J. Li,Y. Cheng,C. Bai,J. Xu,L. Shen,J. Li, Z. Zhou,Z. Li, Y. Chi, X. Yu, E. Li, N. Xu,T. Liu,W. Lou, Y. Bai, X. Yuan,X. Wang, Y. Yuan, J. Chen, S. Guan

ESMO Open（2022）

引用 5|浏览7

暂无评分

摘要

•Treatment-related hypertension, proteinuria, or hemorrhage is associated with longer survival in NETs.•The association is confirmed by the BIIRC assessments and 4-week landmark analysis.•TRAEs can be biomarkers to predict antitumor efficacy in patients with NET.

查看译文

关键词

neuroendocrine tumor,surufatinib,SANET,biomarker,adverse event

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要